Eculizumab: Phase II/III started

Alexion began a double-blind, placebo-controlled, international Phase II/III trial to evaluate IV eculizumab given on the day of transplant and then 18-24 hours later in 286 patients. The trial is enrolling dialysis-dependent patients with renal failure who are to receive a first kidney transplant from a deceased donor at high-risk of developing DGF. ...